Dan Leonard, President, National Pharmaceutical Council

Health care spending in the United States is at the center of a loud, fractured debate mired in deep complexity.

Several groups have developed value assessment frameworks that consider the value of new treatments, yet most models fall short balancing the evaluation of treatment costs with the consideration of benefits to the patient.

Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.

Many healthcare stakeholders are concerned that pharmacy benefit managers use perverse incentives that work against healthcare goals, such as improved outcomes and lower costs.

Physician-, payer-, and patient-based organizations are increasingly developing frameworks that measure the value of a treatment and define it in terms of specific target audiences.

Healthcare stakeholders must work with regulators and policy makers to reduce barriers that prevent the alignment of a drug’s value and price.